BRAINSTORM CELL THERAPEUTICS (BCLI)
US10501E2019 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to BCLI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 88.61% above the current price.
BCLI was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about BCLI.
In the previous month the buy percentage consensus was at a similar level.
BCLI was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-09-28 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-03-31 | Maxim Group | Maintains | Buy |